FORT LAUDERDALE, Fla.--(BUSINESS WIRE)--Jan. 18, 2006--Andrx Corporation (Nasdaq: ADRX) ("Andrx" or the "Company") announced today that the U.S. District Court for the Eastern District of Missouri granted motions for summary judgment filed by Andrx and two other pharmaceutical companies with respect to each company's abbreviated new drug applications (ANDA) for the generic version of Toprol-XL(R) (metoprolol succinate extended-release tablets). The District Court held that the patents asserted by AstraZeneca AB, Aktiebolaget Hassle and AstraZeneca LP (collectively "Astra"), are both invalid due to double patenting and are unenforceable due to inequitable conduct.
